Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

Xin-Xin Cao, Jie Jin, Cheng-Cheng Fu, Shu-Hua Yi, Wei-Li Zhao, Zi-Min Sun, Wei Yang, Deng-Ju Li, Guo-Hui Cui, Jian-da Hu, Ting Liu, Yong-Ping Song, Bing Xu, Zun-Min Zhu, Wei Xu, Ming-Zhi Zhang, Ya-Min Tian, Bin Zhang, Ren-Bin Zhao, Dao-Bin Zhou, Xin-Xin Cao, Jie Jin, Cheng-Cheng Fu, Shu-Hua Yi, Wei-Li Zhao, Zi-Min Sun, Wei Yang, Deng-Ju Li, Guo-Hui Cui, Jian-da Hu, Ting Liu, Yong-Ping Song, Bing Xu, Zun-Min Zhu, Wei Xu, Ming-Zhi Zhang, Ya-Min Tian, Bin Zhang, Ren-Bin Zhao, Dao-Bin Zhou

Abstract

Background: Orelabrutinib is a novel, small molecule, selective irreversible Bruton tyrosine kinase inhibitor. The purpose of this study was to evaluate the efficacy and safety of orelabrutinib in patients with relapsed or refractory Waldenström's macroglobulinemia (R/R WM).

Methods: This is a prospective, multicenter study of orelabrutinib in patients with WM who had at least one prior line of treatment. Orelabrutinib was administered orally at a daily dose of 150 mg until disease progression or unacceptable toxicity. The primary endpoint was major response rate (MRR) assessed by the Independent Review Committee (IRC) according to IWWM-6. This study is registered with ClinicalTrials.gov, NCT04440059. This trial was also registered on Center for Drug Evaluation (www.chinadrugtrials.org.cn) in March 2019, with a number of CTR2019036.

Findings: Between August 2019 and December 2020, 66 R/R WM patients were assessed for eligibility. Forty-seven eligible patients were evaluated for efficacy at a median follow-up of 16.4 months (interquartile range: 12.5, 19.5). As assessed by IRC, the MRR was 80.9%, and the overall response rate was 89.4%. The median time to at least a minor response was 1.9 months. The PFS rates was 89.4% at 12 months. For patients with MYD88L265P /CXCR4NEG, MYD88L265P /CXCR4 S338X, and MYD88NEG /CXCR4NEG mutations, the MRRs were 84.6%, 100%, and 25.0%. Most adverse events were Grades 1 or 2 (91.0%). The common grade 3 or higher adverse events occurring were neutropenia (10.6%), thrombocytopenia (6.4%), and pneumonia (4.3%). Serious adverse events (SAE) occurred in 10 patients (21.3%). One treatment-related death was reported (hepatitis B reactivation).

Interpretation: Orelabrutinib has shown good efficacy and manageable safety profiles in patients with R/R WM.

Funding: InnoCare Pharma.

Keywords: BTK; CXCR4; MYD88; Orelabrutinib; Waldenström's Macroglobulinemia.

Conflict of interest statement

DBZ, XXC, JJ, ZZF, SHY, WLZ, ZMS, WY, DJL, GHC, JDH, TL, YPS, BX, ZMZ, WX, and MZZ declare no competing interests. YMT, BZ, and RBZ are employees of InnoCare Pharma.

© 2022 The Author(s).

Figures

Figure 1
Figure 1
Trial profile. * One patient discontinued treatment due to noncompliance.
Figure 2
Figure 2
Waterfall plot of best percent change from baseline in IgM (a) and maximum improvement in hemoglobin concentration over time (b). Hgb: hemoglobin; IgM: immunoglobulin M; Error bars denote 95% CI.
Figure 3
Figure 3
Subgroup analysis. ECOG: Eastern Cooperative Oncology Group; IgM: immunoglobulin M; MRR: major response rate; NA: not available.
Figure 4
Figure 4
PFS Kaplan-Meier curve (ITT) (a) and PFS by genotype (b). NA: not available.

References

    1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110–115.
    1. Anderson K, Alsina M, Bensinger W, et al. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:1211–1219.
    1. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter Z. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791–2796.
    1. Treon SP, Xu L, Guerrera M, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38:1198–1208.
    1. Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström's macroglobulinema: chances and challenges. Leukemia. 2021;35:333–345.
    1. Gustine JN, Xu L, Yang G, et al. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021;194:730–733.
    1. Vinarkar S, Arora N, Chowdhury SS, et al. MYD88 and CXCR4 mutation profiling in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinaemia. Indian J Hematol Blo. 2019;35:57–65.
    1. IMBRUVICA® (ibrutinib): prescribing information 2020. . Accessed 7 April 2022.
    1. BRUKINSA® (zanubrutinib): prescribing information 2021. . Accessed 7 April 2022.
    1. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for Waldenström macroglobulinaemia. Lancet Haematol. 2020;7:e827–e837.
    1. Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39:565–575.
    1. Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2021;136:2027–2037.
    1. Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9
    1. Zhang B, Zhao R, Liang R, et al. AACR Annual Meeting. Vol. 80. 2020. Orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties. CT132.
    1. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240–252.
    1. Song Y, Song Y, Liu L, et al. Safety and efficacy of orelabrutinib monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study. Blood. 2019;134(suppl 1):755.
    1. Xu W, Song Y, Wang T, et al. Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: updated long term results of phase II study. Blood. 2021;138(suppl 1):2638.
    1. Dhillon S. Orelabrutinib: first approval. Drugs. 2021;81:503–507.
    1. Wu Y-Y, Jia M-N, Cai H, et al. Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia. Ann Hematol. 2020;99:1763–1769.
    1. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160:171–176.
    1. Despina F, Meletios Athanasios D, Efstathios K. Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opin Emerg Dr. 2020;25:433–444.
    1. Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther-Oncolyt. 2021;21:158–170.
    1. Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-Cell malignancies. Blood. 2018;132(Suppl 1):1871. (abstr)
    1. Dimopoulos M, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–250.
    1. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
    1. Owen R, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7:e112–e121.
    1. Sekiguchi N, Rai S, Munakata W, et al. Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. Cancer Sci. 2022;113:2085–2096.
    1. An G, Zhou D, Cheng S, et al. A phase II trial of the bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory Waldenström macroglobulinemia. Clin Cancer Res. 2021;27:5492–5501.
    1. Dimopoulos M, Garcia-Sanz R, Lee H-P, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4:6009–6018.
    1. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038–2050.
    1. Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918–3927.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir